tbuckley/cabot-search huggingface dataset:
EPID-21. THE NATIONAL SPECTRUM OF NEWLY-DIAGNOSED BRAIN TUMORS IN ADULT PATIENTS VARIES SIGNIFICANTLY BY PATIENT DEMOGRAPHICS
Authors: Matthew Torre, Mustafa Ascha, Maya Harary, Timothy Smith, Ayal Aizer, Keith Ligon, David Reardon, Jill Barnholtz-Sloan, Bryan Iorgulescu
Journal: Neuro-Oncology (2019)

Abstract INTRODUCTION Herein we examine the epidemiology and outcomes of the entire spectrum of intracranial tumors in the contemporary era. METHODS Adult patients (≥20yo) presenting between 2010–2015 where the first evidence of cancer involves an intracranial tumor were queried from the National Cancer Database, which comprises &gt;70% of cancers newly-diagnosed in the U.S. Tumor types were classified by WHO2016 ICD-O3, and stratified by patient characteristics. RESULTS 361,841 adults without a history of cancer presented with intracranial tumors between 2010–2015. Across all ages, these were comprised of 1) brain metastases (BMs; 25%: 29% in males vs. 23% in females); 2) meningiomas (25%: 15% in males, but 34% in females) including atypical (n=4,565) and anaplastic (n=833); 3) diffuse infiltrative gliomas (21%: 26% in males vs. 17% in females), mostly GBMs (14%); followed by 4) sellar (14%), 5) cranial nerve (6%), and PCNSL (3%) tumors. The remaining types each comprised ≤2 % of brain tumors, including mesenchymal non-meningothelial tumors (2%), intracranial ependymal (0.8%), mixed neuronal-glial (0.7%), circumscribed “other astrocytomas” (0.6%, mostly pilocytic astrocytomas n=1,307 and PXAs n=272), CNS embryonal (0.3%), pineal (0.2%), GCTs (0.1%), and choroid plexus (0.1%) tumors. In the 91,686 patients presenting with a BM, the most common primaries were lung adenocarcinoma (39%), lung SmallCC (14%), lung SqCC (8%), breast (8% of females), melanoma (3%), kidney (3%), colorectal (2%), and esophageal (1%). The distributions of brain tumor types differed significantly by age, sex, race/ethnicity, and insurance status. CONCLUSIONS In adult patients where the first manifestation of cancer includes an intracranial tumor, the most common diagnosis is either metastatic disease (predominantly from NSCLC) in males or benign meningiomas in females; but varies substantially by age group. Notably, our results adjust the traditional teaching that half of all new brain masses are BMs, which in fact represent only ~25% of new intracranial masses.
Combining CDK2/9 Inhibitor CYC065 with Venetoclax, a BCL2 Inhibitor, to Treat Patients with Relapsed or Refractory AML or MDS
Authors: Gautam M. Borthakur, Tapan M. Kadia, Hind Al Azzawi, Daniella Zheleva, David Blake, Judy H Chiao
Journal: Blood (2019)
Loss of ZnT8 function protects against diabetes by enhanced insulin secretion
Authors: Om Prakash Dwivedi, Mikko Lehtovirta, Benoit Hastoy, Vikash Chandra, Nicole A. J. Krentz, Sandra Kleiner, Deepak Jain, Ann-Marie Richard, Fernando Abaitua, Nicola L. Beer, Antje Grotz, Rashmi B. Prasad, Ola Hansson, Emma Ahlqvist, Ulrika Krus, Isabella Artner, Anu Suoranta, Daniel Gomez, Aris Baras, Benoite Champon, Anthony J. Payne, Daniela Moralli, Soren K. Thomsen, Philipp Kramer, Ioannis Spiliotis, Reshma Ramracheya, Pauline Chabosseau, Andria Theodoulou, Rebecca Cheung, Martijn van de Bunt, Jason Flannick, Maddalena Trombetta, Enzo Bonora, Claes B. Wolheim, Leena Sarelin, Riccardo C. Bonadonna, Patrik Rorsman, Benjamin Davies, Julia Brosnan, Mark I. McCarthy, Timo Otonkoski, Jens O. Lagerstedt, Guy A. Rutter, Jesper Gromada, Anna L. Gloyn, Tiinamaija Tuomi, Leif Groop
Journal: Nature Genetics (2019)
Rituximab-CHOP and Central Nervous System Prophylaxis Using Intrathecal Methotrexate in Primary Breast Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm Phase II Study
Authors: Ho-Young Yhim, Cheolwon Suh, Seok Jin Kim, Deok-Hwan Yang, Hyeon-Seok Eom, Kyoung Ha Kim, Yong Park, Jin Seok Kim, Hyo Jung Kim, Dok Hyun Yoon, Won Seog Kim, Jae-Yong Kwak
Journal: Blood (2019)
Treatment of Anemia in Transfusion-Dependent and Non-Transfusion-Dependent Lower-Risk MDS: Current and Emerging Strategies
Authors: Ulrich Germing, Ester N. Oliva, Devendra Hiwase, Antonio Almeida
Journal: HemaSphere (2019)

Abstract Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow disorders with a highly diverse clinical course. For lower-risk MDS patients, therapeutic objectives aim to correct chronic anemia and improve/maintain health-related quality of life (HRQoL). However, disease burden is often insufficiently recognized, and although some patients do not respond/lose response to standard treatment, many are treated late. This is the case for non-transfusion-dependent patients with symptomatic anemia, in whom delayed treatment initiation may lead to unnecessary morbidity. Current active treatment options for lower-risk MDS are limited. Standard care for lower-risk 5q deletion [del(5q)] MDS patients with anemia remains supportive, consisting of red blood cell (RBC) transfusions, iron chelation therapy, and treatment with erythropoiesis-stimulating agents (ESAs) in the case of low serum erythropoietin levels. Response rates to ESAs range from 15% to 63%, whereas 56% to 67% of patients with del(5q) MDS achieve RBC transfusion independence with lenalidomide. Treatment options for patients’ refractory to ESAs and/or lenalidomide, however, are limited. Frequent transfusions are associated with profound clinical, HRQoL, and economic consequences for transfusion-dependent patients. This review focuses on the multiple unmet clinical needs that exist in the treatment of anemia associated with lower-risk MDS and the current and future treatment options that may improve disease management and patient outcomes.
EXTH-57. PRECLINICAL COMBINATION OF ONC201 WITH RADIOTHERAPY OR TEMOZOLOMIDE IN GBM, DIPG AND ATRT CELL LINES RESULTS IN DOPAMINE RECEPTOR ANTAGONISM, ATF4 INDUCTION AND CELL DEATH
Authors: Lanlan Zhou, Wafik El-Deiry
Journal: Neuro-Oncology (2019)

Abstract CNS tumors are one of the most lethal cancers in children and young adults. We previously reported that first-in-class small-molecule imipridone ONC201 can antagonize dopamine receptor D2 (DRD2), inactivate ERK/AKT, induce the integrated stress response (ISR), upregulate pro-apoptotic TRAIL receptor DR5, deplete cancer stem cells, and induce growth arrest or cell death in tumor cells. ONC201 crosses the blood-brain barrier and has induced durable tumor regressions in adult and pediatric H3K27M-mutant glioma patients. We hypothesized that ONC201 may synergize with radiotherapy or temozolomide in brain tumors. Glioblastoma (GBM: SNB19, T98G and U251), diffuse intrinsic pontine glioma (DIPG: SF8628) and atypical teratoid rhabdoid tumor (ATRT: BT-12, BT-16) cell lines were tested using cell viability or colony formation assays with ONC201 up to 20 μM alone or in combination with radiotherapy up to 8 Gy or temozolomide up to 100 μM. We observed synergy between ONC201 and radiation or temozolomide by multiple assays. We observed induction of PKA substrate phosphorylation as a marker of DRD2 antagonism, induction of ATF4 as a marker of ISR activation, and multiple markers of cell death in treated brain tumor cells. We are evaluating the relevance of mitochondrial protease ClpP, a recently described binding target of ONC201, in ONC201-induced glioma cell death. We have observed that knockdown of ClpP strongly protects multiple human cancer cell lines from ONC201-mediated cytotoxicity. Thus, we are exploring the potential interplay between ClpP, dopamine receptors, the ISR and TRAIL signaling pathways after single agent or combinatorial treatments. Our data suggests that ONC201 may be combined synergistically with temozolomide or radiation to address gliomas, along with potential pharmacodynamic biomarkers.
PATH-25. APPLICABILITY OF A NOMOGRAM INCLUDING CLINICAL AND MOLECULAR VARIABLES IN THE STRATIFICATION OF RISK GROUPS IN PEDIATRIC MEDULLOBLASTOMA
Authors: Bruna Mançano, Rui Reis, Leticia Leal, Flavia de Paula, Carlos Almeida Jr, Gisele Almeida, Marcus Matushita, Fabio Faustino, Carlos Cavalcante, Fernanda Magalhães, Marco Oliveira
Journal: Neuro-Oncology (2019)

Abstract Medulloblastoma is the most common type of malignant brain tumor that occurs during childhood and adolescence. Currently, this pathology comprises at least four different molecular tumor subtypes (WNT, SHH, group 3 or C and group 4 or D) which have their own molecular characteristics, distinct clinical presentations and are associated with different survival rates. The purpose is to evaluate the applicability of a nomogram that includes clinical and molecular variables in pediatric medulloblastomas in the routine of the Hospital de Cancer de Barretos. The series l consists of 85 pediatric patients from 0 to 18 years old, diagnosed with medulloblastoma attended at the Hospital de Cancer de Barretos (HCB), from January 2000 to December 2017. The molecular subgroups will be performed using the Nanostring technique. This research intends to implement a nomogram that uses several variables known and involved in the treatment and prognosis of patients, this nomogram with multiple variables will show the clinical and molecular effect of each variable to predict disease-free survival and survival overall in 3 and 5 years. Thus, we will have the opportunity to analyze these characteristics in order to improve survival and reduce morbidity and consequently mortality during treatment for the different subgroups of medulloblastomas.
Understanding Pre-Leukemia in Trisomy 21 Human HSC and Modeling Progression Towards Down Syndrome Associated Leukemia Using CRISPR/Cas9 at Single Cell Resolution
Authors: Elvin Wagenblast, Olga I. Gan, Maria Azkanaz, Sabrina A. Smith, Joana Araújo, Lorien Shakib, Jessica L. McLeod, Gabriela Krivdova, Johann K. Hitzler, Eric R. Lechman, John E. Dick
Journal: Blood (2019)
Methylation of immune synapse genes modulates tumor immunogenicity
Authors: Anders Berglund, Matthew Mills, Ryan M. Putney, Imène Hamaidi, James Mulé, Sungjune Kim
Journal: Journal of Clinical Investigation (2019)

Cancer immune evasion is achieved through multiple layers of immune tolerance mechanisms including immune editing, recruitment of tolerogenic immune cells, and secretion of immunosuppressive cytokines. Recent success with immune checkpoint inhibitors in cancer immunotherapy suggests a dysfunctional immune synapse as a pivotal tolerogenic mechanism. Tumor cells express immune synapse proteins to suppress the immune system, which is often modulated by epigenetic mechanisms. When the methylation status of key immune synapse genes was interrogated, we observed disproportionately hypermethylated costimulatory genes and hypomethylation of immune checkpoint genes, which were negatively associated with functional T cell recruitment to the tumor microenvironment. Therefore, the methylation status of immune synapse genes reflects tumor immunogenicity and correlates with survival.
An Injectable Neural Stimulation Electrode Made from an In‐Body Curing Polymer/Metal Composite
Authors: James K. Trevathan, Ian W. Baumgart, Evan N. Nicolai, Brian A. Gosink, Anders J. Asp, Megan L. Settell, Shyam R. Polaconda, Kevin D. Malerick, Sarah K. Brodnick, Weifeng Zeng, Bruce E. Knudsen, Andrea L. McConico, Zachary Sanger, Jannifer H. Lee, Johnathon M. Aho, Aaron J. Suminski, Erika K. Ross, Jose L. Lujan, Douglas J. Weber, Justin C. Williams, Manfred Franke, Kip A. Ludwig, Andrew J. Shoffstall
Journal: Advanced Healthcare Materials (2019)

Implanted neural stimulation and recording devices hold vast potential to treat a variety of neurological conditions, but the invasiveness, complexity, and cost of the implantation procedure greatly reduce access to an otherwise promising therapeutic approach. To address this need, a novel electrode that begins as an uncured, flowable prepolymer that can be injected around a neuroanatomical target to minimize surgical manipulation is developed. Referred to as the Injectrode, the electrode conforms to target structures forming an electrically conductive interface which is orders of magnitude less stiff than conventional neuromodulation electrodes. To validate the Injectrode, detailed electrochemical and microscopy characterization of its material properties is performed and the feasibility of using it to stimulate the nervous system electrically in rats and swine is validated. The silicone-metal-particle composite performs very similarly to pure wire of the same metal (silver) in all measures, including exhibiting a favorable cathodic charge storage capacity (CSC
GENE-31. IDENTIFICATION OF CORE AND CONTEXT-SPECIFIC FITNESS GENES IN GLIOBLASTOMA STEM CELLS VIA GENOME-WIDE CRISPR-Cas9 SCREENS
Authors: Graham MacLeod, Stephane Angers, Peter Dirks, Nishani Rajakulendran, Moloud Ahmadi, Danielle Bozek, Artee Luchman, Sam Weiss
Journal: Neuro-Oncology (2019)

Abstract Advances in the characterization of the genetic, epigenetic and transcriptomic landscapes of glioblastoma (GBM) tumor samples and primary cell lines have yielded considerable insight into tumor initiation and progression. A major finding from these studies is the high degree of inter- and intra-tumoral variability displayed in GBM, which has increased interest in the identification of clinically relevant disease subtypes for precision targeting. While multiple groups have identified subtypes of GBM tumors and GBM stem cell lines, efforts to identify specific actionable targets have yet to bear fruit. To address this gap, we performed genome-wide TKO CRISPR-Cas9 fitness screens to functionally interrogate the genomes of a panel of 16 genetically/epigenetically characterized GBM stem cell lines. Our screens identify over 1,500 fitness genes per GBM stem cell line which collectively provide a functional landscape of genetic vulnerabilities in GBM. The size and heterogeneity of our screen panel provided us with the capability to identify both core (i.e. SOX9, Protein Ufmylation, JUN) and context specific fitness genes. Specifically, we have identified genes preferentially required for the proliferation of GBM stem cells based on transcriptionally defined subtypes (i.e. SOX2, OLIG2 in Proneural GSCs), genetic alterations (i.e. CDK6 in CDKN2A/B deleted GBM) and disease stage (i.e. ATP6AP2 in recurrent GBM). Experimental validation of key subtype-specific fitness genes is currently underway using genetic knockout and drug/inhibitor treatment. Our data provides biological insight and novel mechanistic understanding of heterogeneity in GBM and points to opportunities for precision targeting of defined GBM subtypes.
Validation of Low Risk Prognostic Scoring System (LR-PSS) in Patients with Lower Risk IPSS-R Myelodysplastic Syndrome. Results from a Single Center
Authors: Montserrat Arnan Sangerman, Helena Pomares, Esther Alonso, Mercedes Galiano, Maite Encuentra, Javier Grau, Anna Sureda
Journal: Blood (2019)
Outcome and Genomic Characteristics of Non-Down Syndrome Acute Megakaryoblastic Leukemia in Children Treated with Low-Dose Chemotherapy for Induction Remission
Authors: Yixin Hu, Li Gao, Aili Chen, Jun Lu, Jie Li, Hailong He, Yi Wang, Peifang Xiao, Qianfei Wang, Raul Ribeiro, Shaoyan Hu
Journal: Blood (2019)
Central Nervous System Prophylaxis with High-Dose Intravenous Methotrexate or Intrathecal Chemotherapy in Patients with Diffuse Large B-Cell Lymphoma and High-Risk of CNS Relapse Treated in the Rituximab Era
Authors: Sabela Bobillo, Erel Joffe, Venkatraman Seshan, Ariela Noy, Steven M. Horwitz, M. Lia Palomba, Matthew J Matasar, David J. Straus, Paul A. Hamlin, Connie Lee Batlevi, Paola Ghione, David Sermer, Alison J. Moskowitz, Audrey Hamilton, Philip Caron, Colette Owens, Gottfried R. von Keudell, Ahmet Dogan, Andrew D. Zelenetz, Anas Younes
Journal: Blood (2019)
NICE recommends cannabis based drugs for epilepsy and multiple sclerosis
Authors: Elisabeth Mahase
Journal: BMJ (2019)

In final appraisal documents the UK National Institute for Health and Care Excellence has recommended the use of cannabidiol with clobazam for treating seizures associated with two rare and severe forms of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.12

The decision comes after NICE initially rejected the use of cannabidiol in draft appraisal documents released in August because of concerns over a lack of data on the drug’s long term effectiveness.3

However, in its latest documents NICE has recommended the drug for people aged 2 or over, reporting …
Immune exclusion by naturally acquired secretory IgA against pneumococcal pilus-1
Authors: Ulrike Binsker, John A. Lees, Alexandria J. Hammond, Jeffrey N. Weiser
Journal: Journal of Clinical Investigation (2019)

Successful infection by mucosal pathogens requires overcoming the mucus barrier. To better understand this key step, we performed a survey of the interactions between human respiratory mucus and the human pathogen Streptococcus pneumoniae. Pneumococcal adherence to adult human nasal fluid was seen only by isolates expressing pilus-1. Robust binding was independent of pilus-1 adhesive properties but required Fab-dependent recognition of RrgB, the pilus shaft protein, by naturally acquired secretory IgA (sIgA). Pilus-1 binding by specific sIgA led to bacterial agglutination, but adherence required interaction of agglutinated pneumococci and entrapment in mucus particles. To test the effect of these interactions in vivo, pneumococci were preincubated with human sIgA before intranasal challenge in a mouse model of colonization. sIgA treatment resulted in rapid immune exclusion of pilus-expressing pneumococci. Our findings predict that immune exclusion would select for nonpiliated isolates in individuals who acquired RrgB-specific sIgA from prior episodes of colonization with piliated strains. Accordingly, genomic data comparing isolates carried by mothers and their children showed that mothers are less likely to be colonized with pilus-expressing strains. Our study provides a specific example of immune exclusion involving naturally acquired antibody in the human host, a major factor driving pneumococcal adaptation.
NIMG-01. T2WI-FLAIR MISMATCH SIGN IN LOWER GRADE GLIOMA AND DYSEMBRYOPLASTIC NEUROEPITHELIAL TUMOR
Authors: Shumpei Onishi, Fumiyuki Yamasaki, Motoki Takano, Ushio Yonezawa, Akira Taguchi, Kazuhiko Sugiyama, Kaoru Kurisu
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND T2-FLAIR mismatch sign was reported as a specific imaging marker for diffuse astrocytoma with IDH-mutant and 1p/19q non-codeletion. However, most of the previous studies for T2-FLAIR mismatch were confirmed only among lower grade glioma (LGG). The purpose of this study is to explore the T2-FLAIR mismatch sing in supratentorial non-enhancing tumor including LGG and dysembryoplastic neuroepithelial tumor (DNET) and to unveil the exception rules of the sign. METHODS Forty-four patients of non-enhancing LGG and DNET were included in this study. LGG（diffuse astrocytoma with IDH mutant (IDHmut-Noncodel), oligodendroglioma with IDH-mutant and 1p19q codeletion (IDHmut-Codel), diffuse astrocytoma with IDH wildtype (IDHwt)）and DNET were diagnosed based on WHO 2016 classification. The tumors were evaluated MRI by 2 independent reviewers to assess presence or absence of T2-FLAIR mismatch sign. CT was also performed to evaluate the localized thinning of the skull bone. Inter-reviewer agreement with Cohen’s kappa (κ) was calculated. RESULT: Ten out of 18 cases (55.6%) of IDHmut-Noncodel presented T2-FLAIR mismatch sign. None of the other LGG (IDHmut-Codel and IDHwt) presented T2-FLAIR mismatch. Eight out of 11 cases (72.7%) of DNET also present the T2-FLAIR mismatch. The overlying part of the skull bone thinning was observed in 5 cases of DNET, but none of LGG presented the localized skull bone thinning. The inter-rater agreement for the T2-FLAIR mismatch and the localized thinning of the skull bone were excellent (κ= 1.00). CONCLUSION The T2-FLAIR mismatch sign was specific marker for IDHmut-Noncodel among LGG. However, DNET also presented the T2-FLAIR mismatch sign. The localized skull bone thinning could be useful for differentiating between IDHmut-Noncodel and DNET
Results from a Global Randomized Phase 3 Study of Guadecitabine (G) Vs Treatment Choice (TC) in 815 Patients with Treatment Naïve (TN) AML Unfit for Intensive Chemotherapy (IC) ASTRAL-1 Study: Analysis By Number of Cycles
Authors: Gail J. Roboz, Hartmut Döhner, Marco Gobbi, Patricia L. Kropf, Jiri Mayer, Jürgen Krauter, Tadeusz Robak, Hagop M. Kantarjian, Jan Novak, Wieslaw Jedrzejczak, Xavier Thomas, Mario Ojeda-Uribe, Yasushi Miyazaki, Yoo Hong Min, Su-Peng Yeh, Joseph M Brandwein, Liana Gercheva, Judit Demeter, Elizabeth A. Griffiths, Karen W.L. Yee, Jean-Pierre Issa, Yong Hao, Mohammad Azab, Pierre Fenaux
Journal: Blood (2019)
Using Autoantibodies and Cutaneous Subset to Develop Outcome‐Based Disease Classification in Systemic Sclerosis
Authors: Svetlana I. Nihtyanova, Alper Sari, Jennifer C. Harvey, Anna Leslie, Emma C. Derrett‐Smith, Carmen Fonseca, Voon H. Ong, Christopher P. Denton
Journal: Arthritis & Rheumatology (2019)

To describe the associations between autoantibodies, clinical presentation, and outcomes among patients with systemic sclerosis (SSc) in order to develop a novel SSc classification scheme that would incorporate both antibodies and the cutaneous disease subset as criteria.Demographic and clinical characteristics, including cutaneous subset, time of disease and organ complication onset, and autoantibody specificities, were determined in a cohort of SSc subjects. Survival analysis was used to assess the effect of the autoantibodies on organ disease and death.The study included 1,325 subjects. Among the antibody/skin disease subsets, anticentromere antibody-positive patients with limited cutaneous SSc (lcSSc) (n = 374) had the highest 20-year survival (65.3%), lowest incidence of clinically significant pulmonary fibrosis (PF) (8.5%) and scleroderma renal crisis (SRC) (0.3%), and lowest incidence of cardiac SSc (4.9%), whereas the frequency of pulmonary hypertension (PH) was similar to the mean value in the SSc cohort overall. The anti-Scl-70+ groups of patients with lcSSc (n = 138) and patients with diffuse cutaneous SSc (dcSSc) (n = 149) had the highest incidence of clinically significant PF (86.1% and 84%, respectively, at 15 years). Anti-Scl-70+ patients with dcSSc had the lowest survival (32.4%) and the second highest incidence of cardiac SSc (12.9%) at 20 years. In contrast, in anti-Scl-70+ patients with lcSSc, other complications were rare, and these patients demonstrated the lowest incidence of PH (6.9%) and second highest survival (61.8%) at 20 years. Anti-RNA polymerase antibody-positive SSc patients (n = 147) had the highest incidence of SRC (28.1%) at 20 years. The anti-U3 RNP+ SSc group (n = 56) had the highest incidence of PH (33.8%) and cardiac SSc (13.2%) at 20 years. Among lcSSc patients with other autoantibodies (n = 295), the risk of SRC and cardiac SSc was low at 20 years (2.7% and 2.4%, respectively), while the frequencies of other outcomes were similar to the mean values in the full SSc cohort. Patients with dcSSc who were positive for other autoantibodies (n = 166) had a poor prognosis, demonstrating the second lowest survival (33.6%) and frequent organ complications.These findings highlight the importance of autoantibodies, cutaneous subset, and disease duration when assessing morbidity and mortality in patients with SSc. Our novel classification scheme may improve disease monitoring and benefit future clinical trial designs in SSc.
Ex vivo Engineering of Red Blood Cells
Authors: Jan Frayne, Deborah E Daniels, Jan Frayne, Timothy J Satchwell, Joseph Hawksworth, Belinda K Singleton, Tatyana N Andrienko, Marieangela C Wilson, Sabine Kupzig, Marjolein Meinders, Ryo Kurita, Yukio Nakamura, Ivan Ferrer Vicens, Rebecca Griffiths, Nicola Cogan, Kongtana Trakarnsanga, David J. Anstee, Ashley Mark Toye
Journal: Blood (2019)
A Novel 10-Fluorochrome Multiparameter Flow Cytometry (MFC) Panel for Precise Plasma Cell (PC) and MRD Assessment in Clinical Routine of Multiple Myeloma (MM) Patients and throughout the Disease Course
Authors: Veronika Riebl, Sandra M. Woerner, Dagmar Wider, Marie Follo, Stefan J. Mueller, Cornelius Miething, Mihaela Zlei, Justus Duyster, Ralph Wäsch, Monika Engelhardt
Journal: Blood (2019)